Navigation Links
GTx Announces Presentation of Ostarine and Acapodene Data at 2007,ASCO Annual Meeting

in the Phase III ADT clinical trial.

-- "Prevalence of osteoporosis and osteopenia during androgen deprivation therapy (ADT) for prostate cancer: Baseline data from a large randomized controlled trial." Poster number: F5. Abstract number: 5116.

-- Date and time: June 3, 2007 from 2:00 to 6:00 p.m.

-- Location: S Hall A2

About GTx

GTx, headquartered in Memphis, Tenn., is a biopharmaceutical company dedicated to the discovery, development, and commercialization of small molecules that selectively target hormone pathways to treat cancer, osteoporosis and bone loss, muscle wasting and other serious medical conditions. GTx is developing ACAPODENE(R) (toremifene citrate), a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: first, a pivotal Phase III clinical trial for the treatment of serious side effects of androgen deprivation therapy for advanced prostate cancer, and second, a pivotal Phase III clinical trial for the prevention of prostate cancer in high risk men with high grade prostatic intraepithelial neoplasia, or PIN. GTx has licensed to Ipsen Limited exclusive rights in Europe to develop and commercialize ACAPODENE(R). GTx also is developing Ostarine(TM), a first-in-class selective androgen receptor modulator, or SARM. GTx plans to initiate a Phase IIb Ostarine(TM) clinical trial for cancer cachexia in non-small cell lung cancer patients in June of 2007. GTx plans to initiate a Phase IIb Ostarine(TM) clinical trial for the treatment of chronic kidney disease muscle wasting by the end of 2007. GTx believes that Ostarine(TM) also has the potential to treat a variety of other indications associated with muscle wasting and bone loss including sarcopenia and osteoporosis.

Forward-Looking Information is Subject to Risk and Uncertainty

This press release contains forward-looking statements based upon GTx's current expectations. Forward-looking statements involve risks and uncertaint
'"/>




Page: 1 2 3

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product

Post Your Comments:
(Date:11/6/2009)... PARIS, November 6 , - ...Linezolid for the,Treatment of Multi-Resistant Sta...vexel, a speciality pharmaceutical company focused...tics designed to overcome the significant global,p...at its most advanced oral,antibacterial NXL103 (fl...
(Date:11/5/2009)...OINT RICHMOND, Calif., Nov. 5 /PRNewswire-FirstCal...PT ), a specialty pharmaceutical company focused o...tary products that address important therapeutic n... it will host a webcast and teleconference with ma...esults on Thursday, November 12, 2009, at 5:00 p.m...
(Date:11/5/2009)...ULLERTON, Calif., Nov. 5 Renee Cob...ate professor of dermatology at the University of ...nts are experiencing tremendous results with Therm...ed for skin tightening and contouring, features a ...efficacy and improves patient comfort. ,, "The...
Breaking Medicine Technology:Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 3Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 4Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12 2Orange County Dermatologist Garners Outstanding Results With New Thermage CPT(R) 2What are the most effective ways of promoting physical exercise in adults 3F 51564 1What are the most effective ways of promoting physical exercise in adults 3F 51564 2What are the most effective ways of promoting physical exercise in adults 3F 51564 3Novel drug discovery tool could identify promising new therapies for Parkinsons disease 13001 1Novel drug discovery tool could identify promising new therapies for Parkinsons disease 13001 2Novel drug discovery tool could identify promising new therapies for Parkinsons disease 13001 3Novel drug discovery tool could identify promising new therapies for Parkinsons disease 13001 4Pelosi Statement on Appointment of Dr Regina Benjamin as Surgeon General of the United States 51560 1
...or Cancer Research meeting indicate that technolo...-water-soluble drugs to treat cancer and possibly ...r Pharmaceuticals today,reported results on a nove...pable of dissolving in water (hydrophobic drugs) i...ation. These findings allow the company to,combine...
...MOND, Va., April 16 Insmed Inc. (Nasdaq:,INSM), a...ticals, today,announced that it has received appro...care products Regulatory Agency (MHRA) to initiate...n biologic (FOB) product candidate.,Insmed,s INS-1...a follow-on,biologic of the FDA-approved product N...
Other Medicine Technology:Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations 2Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations 3Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R) 2Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R) 3Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R) 4
(Date:11/8/2009)...te Shows Who Sides With Working Families vs. Insur...ewswire-USNewswire/ -- On the heels of an historic...or a good, balanced health care reform bill, the P...r state,s U.S. representatives voted on HR 3962, t...The legislation, which passed Saturday evening by ...
(Date:11/7/2009)..., The American Medical ...Rush Award for Citizenship and Community Service t...icago, IL. The award recognizes physicians who hav... duty to make an outstanding public service contri...d the award today during the opening session of th...
(Date:11/7/2009).... 7 With the final Hous...tremists are holding the entire bill hostage to fu...g that the bill go far beyond the status quo restr...o the original bill. In an outrageous amendment, ...ternoon, antichoice Democrats are demanding explic...
(Date:11/7/2009)...e Public Relations Society of America (PRSA) will ...Gage Lofgren, senior vice president of Brand Strat...tonight at a ceremony at PRSA,s 2009 International...o the PRSA College of Fellows is one of the profes...rman, APR, SAGE, Fellow PRSA, and 2009 chair of th...
(Date:11/7/2009)... Forget ‘sweatox’ or ‘Boytox&...age of the anti-ageing jab ‘Breastox’ ... the décolletage, can reduce the appearance...round the breasts, leaving smoother, younger-looki...er 7, 2009 -- Transform, the UK’s largest gr...
Breaking Medicine News(10 mins):Health News:Robert Brady (D-PA-1), Chaka Fattah (D-PA-2), Kathy Dahlkemper (D-PA-3), Joe Sestak (D-PA-7), Patrick Murphy (D-PA-8), Christopher Carney (D-PA-10), John Murtha (D-PA-12), Paul Kanjorski (D-PA-11), Allyson Schwartz (D-PA-13), Mike Doyle (D-PA-14) Ge 2Health News:AMA Honors IL Ophthalmologist Manus C. Kraff M.D. for Volunteer Eye Care for Military Members 2Health News:PRSA Inducts Head of Public Relations for Kaiser Permanente Into the College of Fellows for Contributions to the Profession and Lifetime Achievement 2Health News:PRSA Inducts Head of Public Relations for Kaiser Permanente Into the College of Fellows for Contributions to the Profession and Lifetime Achievement 3Health News:UK Boobs Get a Boost with 'Breastox' 2
... after revelation that Peanut Corp. of America shi...break, FDA announces , , FRIDAY, Jan. 30 (...criminal investigation into the salmonella outbrea...e criminal violations at the Georgia processing pl...
...an. 30 Americans resolving to eat healthier and m...e also likely to look for ways to trim their groce...reasing nutritional intake? Dr. Praeger,s Sensible...hier lifestyle choices during tough economic times...
...S. Vincent Grasso, a member of the Stevens Healthc...rd was selected to lead the technical team on a $5...AA compliant, web-based data entry and reporting p...or HIV Women of Color. The grant proposal brings t...
...matic brain injury (TBI) has been identified as th...nistan. , TBI is known to cause deficits in mem...s in conjunction with post-traumatic stress disord...gathered by the Veterans Administration,s (VA) Qua...
...rnors Association Center meeting highlights IBC,s ...nitiative in southeastern PA , , PHILADELPHIA, Ja...nt of Health Services Richard Snyder, MD, yesterda...nter meeting for Best Practices in New Orleans. La...
.... 30 Stryker Corporation (NYSE: SYK ) announced...Wednesday, May 20, 2009, at 8:00 a.m. Eastern Time..., President and Chief Executive Officer, will host...r,s website at www.stryker.com via the For Inves...
Other Medicine News:Health News:U.S. Launches Criminal Probe Into Salmonella Outbreak 2Health News:U.S. Launches Criminal Probe Into Salmonella Outbreak 3Health News:Lower Your Grocery Bill, Improve Health In 2009: Top Tips From Dr. Praeger's Sensible Foods 2Health News:Lower Your Grocery Bill, Improve Health In 2009: Top Tips From Dr. Praeger's Sensible Foods 3Health News:Grasso leads technical team's response to HHS HIV/AIDS Bureau announcement 2Health News:Grasso leads technical team's response to HHS HIV/AIDS Bureau announcement 3Health News:Study of Iraq veterans' traumatic brain injuries to be conducted by UB researchers 2Health News:Patient-Centered Medical Homes Can Improve Care, Reduce Costs; Independence Blue Cross Medical Executive Discusses Innovative PA Program With Nation's Health Care Policy Makers 2Health News:Patient-Centered Medical Homes Can Improve Care, Reduce Costs; Independence Blue Cross Medical Executive Discusses Innovative PA Program With Nation's Health Care Policy Makers 3Health News:Stryker to Host Analyst Meeting 2
...e any trocar system you've ever seen., ,The OnePo...n one designed to be versatile, operationally fle...., ,By offering options in disposability and blad...ctively address the individual preferences of the ...
Reusable Thoracoscopy Cannula
...separate components: an exchange rod, a dilating o...ent trocar sleeve. The exchange rod is a rigid cyl... dilating obturator is tapered and threaded at the...the 10/11mm or the 12mm ENDOPATH surgical trocar. ...
...trocar should be a seamless part of any procedure,...e process. So we spent over three years designing ...g surgeons., ,Introducing the ENDOPATH® Xcel&...unencumbered, hassle-free, laparoscopic access., ...
Medicine Products: